Gyre Therapeutics Quarterly Cash Flow Statement
NASDAQ: GYREHealthcareBiotechnologyUSD
7.04+0.28 (+4.14%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gyre Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Gyre Therapeutics generated -$16.7 million of operating cash flow and spent $262,000 on capital expenditures. That left free cash flow of -$17.0 million, a free-cash-flow margin of -58.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Gyre Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -22.99M | -9.86M | -1.37M | 8.54M | -1.03M | 3.73M | 569.00K | 2.86M | 4.54M | 9.94M | -100.98M | 7.51M |
| Net Income growth (YoY) | — | -364.01% | -340.07% | +199.16% | -122.74% | -62.42% | — | -61.97% | +20.37% | +135.59% | — | — |
| Depreciation & Amortization | 1.48M | 672.00K | 656.00K | 281.00K | 1.01M | 535.00K | 461.00K | 445.00K | 228.00K | 415.00K | 298.00K | 192.00K |
| Stock-Based Compensation | 2.08M | 2.58M | 4.60M | 617.00K | 1.44M | 507.00K | 567.00K | 237.00K | 16.00K | 11.00K | 6.88M | 98.00K |
| Change in Working Capital | -1.65M | 6.79M | -6.97M | 56.00K | 79.00K | -7.79M | 849.00K | -210.00K | -1.44M | -2.21M | 1.05M | 1.12M |
| Operating Cash Flow | -16.73M | 3.18M | -5.63M | 14.24M | -7.47M | -129.00K | -2.76M | 1.73M | -5.49M | 2.88M | 3.36M | 7.58M |
| Capital Expenditures | -262.00K | -178.00K | -144.00K | -589.00K | -335.00K | -122.00K | 65.00K | -693.00K | -1.46M | -231.00K | -2.32M | -1.97M |
| Investing Cash Flow | 9.76M | -3.06M | 1.85M | -5.64M | 1.35M | 1.97M | -2.00M | -2.39M | -8.27M | -7.22M | 1.34M | -5.40M |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | -1.50M |
| Financing Cash Flow | -8.00K | 21.00K | 318.00K | 2.47M | 20.25M | 1.34M | 964.00K | 324.00K | 156.00K | 658.00K | 15.24M | -1.48M |
| Net Change in Cash | -6.34M | 431.00K | -3.33M | 11.27M | 14.09M | 3.23M | -4.05M | -231.00K | -13.69M | -3.72M | 7.43M | 2.35M |
| Free Cash Flow | -16.99M | 3.00M | -5.77M | 13.65M | -7.81M | -251.00K | -2.69M | 1.03M | -6.95M | 2.65M | 1.04M | 5.61M |
This table shows 12 quarterly periods of Gyre Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GYRE's reporting calendar. What is a cash flow statement?